Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of August 2015, specifically dated August 6, 2015. The report discloses a change in beneficial ownership by a market maker, IBI Investment House Ltd., as required by Israeli Securities Regulations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding shareholding changes rather than a financial performance report.
Material Changes
- Shareholder Activity: IBI Investment House Ltd., acting as a market maker, increased its holding of ordinary shares by 83,806 shares.
- Previous Balance: The holder's balance in the previous summary report was 0 shares.
- Current Ownership: The maximum holding percentage during the reported period was 0.03% on a fully diluted basis.
- Share Type: The shares acquired are not treasury shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific transaction involving IBI Investment House Ltd.
Key Facts for Investor Verification
- Verify the identity of the registrant as BiondVax Pharmaceuticals Ltd., distinct from the company name mentioned in the request metadata.
- Confirm the increase of 83,806 shares held by IBI Investment House Ltd. as of August 6, 2015.
- Note that the market maker's total ownership remains minimal at 0.03% of the fully diluted share count.
- Understand that this filing contains no financial performance data or strategic updates.